ALK and non-small cell lung carcinoma: This is, to our knowledge, the first nationwide study in Greece to examine real-world prescribing patterns, TKI utilization, and the prevalence of patients with NSCLC harboring EGFR mutations or ALK rearrangements during the period 2020–2022.